Marinella Clerico

Clinical and Biological Sciences Department, University of Torino, San Luigi Gonzaga Hospital

Affiliated withUniversity of Torino, San Luigi Gonzaga Hospital

Research Area

Biography

Marinella Clerico has not added Biography.
If you are Marinella Clerico and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 21	2016

Other Publications

Article	Year
High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. Journal of the neurological sciences\| PubMed ID: 15240190	2004
The importance of maintaining effective therapy in multiple sclerosis. Journal of neurology\| PubMed ID: 16170500	2005
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology\| PubMed ID: 17190964	2006
Interferon-beta1a for the treatment of multiple sclerosis. Expert opinion on biological therapy\| PubMed ID: 17373904	2007
Adherence to interferon-beta treatment and results of therapy switching. Journal of the neurological sciences\| PubMed ID: 17376486	2007
The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clinical neurology and neurosurgery\| PubMed ID: 18164542	2008
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. Journal of neurology\| PubMed ID: 18825438	2008
Risk factors for tumor occurrence in patients with myasthenia gravis. Journal of neurology\| PubMed ID: 19330280	2009
T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Annals of neurology\| PubMed ID: 19475668	2009
Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose. Journal of neuroimmunology\| PubMed ID: 20573405	2010
Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 22219326	2012
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC neurology\| PubMed ID: 22390218	2012
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA neurology\| PubMed ID: 24977406	2014
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA neurology\| PubMed ID: 25048026	2014
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β. Journal of leukocyte biology\| PubMed ID: 25097195	2014
Epigenetic therapy for Friedreich ataxia. Annals of neurology\| PubMed ID: 25159818	2014
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. Journal of neurology\| PubMed ID: 26410746	2015
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurology(R) neuroimmunology & neuroinflammation\| PubMed ID: 26819963	2016
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study. Expert opinion on drug delivery\| PubMed ID: 26909646	2016
Influence of cigarette smoking on ALS outcome: a population-based study. Journal of neurology, neurosurgery, and psychiatry\| PubMed ID: 27656044	2016